AstraZeneca wagers $200M on Ionis’ next chance at a rare disease drug
AstraZeneca is betting that Ionis' second drug for transthyretin amyloidosis, or ATTR, will stand out where its first one couldn't.
Ionis developed Tegsedi for years...
IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.